Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 1004.31 mg; potassium clavulanate, quantity: 151.917 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; dichloromethane; microcrystalline cellulose; sodium starch glycollate; isopropyl alcohol; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo forte 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate, quantity: 13.58 mg/ml (equivalent: clavulanic acid, qty 11.4 mg/ml); amoxicillin trihydrate, quantity: 91.84 mg/ml (equivalent: amoxicillin, qty 80 mg/ml) - suspension, powder for - excipient ingredients: citric acid; guar gum; sodium citrate; purified talc; aspartame; silicon dioxide; flavour - short-term treatment of the following bacterial infections when caused by sensitive organisms: skin and skin structure infections; urinary tract infections (complicated and uncomplicated); upper respiratory tract infections including sinusitis and otitis media; lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam duo 400/57 should not require the addition of another antibiotic due to the amoxycillin content of curam duo 400/57.

Ireland - English - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - loperamide hydrochloride - orodispersible tablet - 2 milligram(s) - antipropulsives; loperamide

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - clavulanic acid, quantity: 11.4 mg/ml; amoxicillin, quantity: 80 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; succinic acid; colloidal anhydrous silica; aspartame; xanthan gum; hypromellose; flavour - augmentin duo 400 oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology). skin and skin structure infections: urinary tract infections (complicated and uncomplicated): upper respiratory tract infections including sinusitis, otitis media: lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is good reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo 400, should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo 400.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 148.91 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 151.92 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Canada - English - Health Canada

mcneil consumer healthcare division of johnson & johnson inc - loperamide hydrochloride - tablet (orally disintegrating) - 2mg - loperamide hydrochloride 2mg - antidiarrhea agents

Canada - English - Health Canada

mcneil consumer healthcare division of johnson & johnson inc - loperamide hydrochloride - solution - 2mg - loperamide hydrochloride 2mg - antidiarrhea agents